Introduction
Cell proliferation occurs at different rates depending on extracellular factors and the genetic profile of cells, which determines their pluripotency, differentiation status and eventually their transformation grade. The proliferation rate is regulated by proteins involved in the control of the cell cycle, which is driven by cyclins and their associated kinases (Cdk for cyclin-dependent kinase) (Morgan, 1997) . The fluctuating activities of several Cdk/cyclin complexes establish the progression of the cell cycle through each phase (G1, S, G2 and M). The composition and regulation of Cdks vary according to cell type and environment. In the past few years, numerous mouse models have been generated targeting one or more components of the cell cycle machinery (reviewed by Pagano and Jackson (2004) ; Aleem and Kaldis (2006) ; Santamaria and Ortega (2006) ), and in this review, we will outline how the lack of Cdk/cyclin complexes can affect cells (and organism) that rely on their proliferation status. We will report new insights that these mouse models provide to understand proliferation control in stem cells, differentiated cells and transformed cells. To a certain degree, these mouse models mimic drugs that target these cell cycle proteins and interpretation of the observed mutant phenotypes can improve our strategies for cancer therapy.
Cell proliferation is a tightly regulated process and most eukaryotic cells undergo cell division only in the presence of mitogenic factors. The cell cycle machinery includes several mechanisms to sense the presence of these growth factors, inhibitory factors or damage that prevents cell cycle progression. Different checkpoints along the cell division cycle determine progression or arrest and eventually may trigger cell death. At the onset of the cell cycle, mitogenic factors stimulate the expression of proto-oncogenes, such as Ras or Myc, which results in transcriptional regulation leading to increased proliferation. The family of D-type cyclins is the first to be induced through these mitogenic pathways, followed by the expression of cyclins E1 and E2. The D-type cyclins stimulate the activity of Cdk4/Cdk6, whereas E-type cyclins enhance Cdk2 activity. These complexes lead to passage through the restriction (R) point at the boundary of the G1 and S phase, where after the cell cycle progresses independently of growth factors. The key event in the G1 phase is the phosphorylation of the pocket proteins (Retinoblastoma protein (Rb), p107, p130) by Cdk/cyclin D and E complexes. Each Cdk complex phosphorylates presumably distinct residues of Rb (and the other pocket proteins), and it has been postulated that this specificity provides a mechanism for temporal control of Rb during G1 (reviewed by Mittnacht (1998) ; Knudsen and Knudsen (2006) ). Phosphorylation of Rb leads to the release of E2F proteins, resulting in the transcription of genes essential for entry into S phase. When mitogenic signals are not strong enough to enhance Cdk activity and inactivate Rb, cells cannot enter into S phase but eventually will exit the cell cycle and acquire a reversible non-replicative state, quiescence or G0. The G1/S transition can also be affected by inhibitory signals (e.g., cell contact inhibition or by different stresses, such as oxidative stress, DNA damage, etc) inducing the expression of anti-proliferative signals. Tumor suppressor genes constitute these signaling pathways, which result in the inhibition of Cdk activity . The INK4  (p15  Ink4b , p16   Ink4a   , p18  Ink4c and p19   Ink4d   ) and the CIP/KIP  (p21   Cip1   , p27 Kip1 and p57
Kip2
) families inhibit cyclin D and E complexes, respectively, and are among these tumorsuppressor genes (reviewed by Sherr and Roberts (1999) ). Consistently, mice with defects in Cdk inhibitors (CKIs) are cancer prone (reviewed by Santamaria and Ortega (2006) ). Moreover, expression of some of these CKIs is directly or indirectly regulated by p53, one of the major tumor-suppressor genes (reviewed by Vousden and Lu (2002) ). The activation of p53 or Rb under stress conditions can irreversibly affect cells that will enter senescence, a permanent non-replicative state (reviewed by Campisi (2005) ). Cell-cycle progression can also be blocked at other checkpoints (intra S phase, G2/M, mitosis) following cellular damage. These pathways usually activate p53 and/or p21, which will then inhibit Cdk2 and/or Cdk1 activity. At all the checkpoints, cells remain arrested until damage is repaired or cells undergo apoptosis. If cell death is avoided and cell cycle arrest is bypassed, it might lead to cell transformation. The balance between mitogenic, anti-mitogenic, apoptotic and stress response signals determines the fate of the cells and their ability to proliferate.
Embryonic stem (ES) cells proliferate at a fast rate (cell cycle length of B8 h) and exhibit a short G1 phase ( Figure 1a) . Mouse ES cells are deficient in cyclin D-associated activity (Savatier et al., 1996; Burdon et al., 2002; Jirmanova et al., 2002) and rely on Cdk2 activity to drive the G1/S transition (Stead et al., 2002) . Components of the G1 checkpoint, such as Rb are permanently inactivated (reviewed by Burdon et al. (2002) ) and despite high levels of p53 expression in mouse ES cells, cell cycle progression is not affected. It appears that the p53-mediated response is inactive because p53 is sequestered into the cytoplasm (Aladjem et al., 1998; Prost et al., 1998) . Indeed, ES cells do not undergo G1/S cell-cycle arrest under stimuli that would normally activate the p53-mediated pathway in somatic cells, whereas the cell-cycle arrest response is restored upon differentiation of ES cells (Aladjem et al., 1998; Prost et al., 1998) . In contrast, the G2/M checkpoint remains active and knockouts of p53 targets, like Btg2, affect the DNA damage-inducible G2/M arrest (Rouault et al., 1996) . At the onset of differentiation, the proliferation rate decreases with an extension of the G1 phase, associated with the establishment of the Rb/E2F pathway regulating the G1/S checkpoint ( Figure 1b) . Lack of Rb and p53 regulation affects cell differentiation and embryogenesis at several stages of development, suggesting an essential role of these proteins in the maintenance of the proper balance between self-renewal and differentiation (reviewed by Miura et al. (2004) ). During the differentiation process, cells will encounter phases of proliferation and quiescence that require a perfect balance between exogenous signals and the cell cycle machinery. Disturbance of this delicate equilibrium can induce premature senescence, as suggested by the study of a hypermorphic p53 mutant mouse resulting in reduced longevity and an early onset of an aging phenotype (Tyner et al., 2002) . Senescence will occur in differentiated cells when they reach a limited number of cell divisions (controlled by the length of telomeres) or upon activation of stress signals. Five major pathways have been identified that enable transformed cells to escape senescence. These include the telomerase, the p53, the Rb, the insulin-like growth factor (IGF)/Akt and the mitochondrial/oxidative stress pathways (reviewed by Miura et al. (2004); Campisi (2005) ). Inappropriate inhibition or activation of these pathways can lead to immortalization and are found individually or in combination in all tumors. Proliferation of most tumor cells mimics the mode of regulation described for ES cells: activation of proto-oncogenes replacing mitogenic signal requirements, high telomerase activity allowing the maintenance of telomeres and permanent self-renewal, loss of tumor-suppressor gene activity that affects cell-cycle arrest and the apoptosis pathways ( Figure 1c ). The loss of tumor-suppressor gene activity is often permanent in tumor cells (LOH, mutations), which distinguishes them from stem cells. In Figure 2 , we have summarized the regulatory pathways that need to be modified for the transition from one cell type to another. These pathways change the proliferation characteristics of cells and regulate Cdk/cyclin activities. We will discuss results derived from the analysis of 'cell cycle' mouse models and how these pathways are affected in these contexts.
Coupling of Cdk/cyclin activities and cell cycle progression
For many years, our understanding of cell cycle progression was based on studies that inhibited Cdk/cyclin activities by different means (e.g., dominant-negative proteins, overexpression of inhibitors, drugs). These approaches taught us that the activity of Cdk/cyclin complexes coincides with cell cycle progression and its inhibition results in cell-cycle arrest or apoptosis. However, these experiments did not target a single cyclin or Cdk, and even rarely a single family, which resulted in off-target effects. Studies using knockout mouse models were needed to deepen our knowledge of specific in vivo functions associated with each cyclin or Cdk. Ultimately, we should be able to choose and target the best pathways in the context of cancer therapy. Such work started in 1995, when two groups reported knockout mice of cyclin D1, with only tissue-specific defects observed in particular cell types (Fantl et al., 1995; Sicinski et al., 1995) . It was the beginning of ongoing research programs, aiming to inactivate Cdks or cyclins in mice and to explore non-redundant functions among these complexes (reviewed by Pagano and Jackson (2004) ; Aleem and Kaldis (2006) ; Santamaria and Ortega (2006) ).
Mouse knockout models for cell cycle regulators Similar to cyclin D1 ablation (and other cyclins), inactivation of Cdk4 or Cdk6 did not prevent cell cycle progression (Rane et al., 1999; Tsutsui et al., 1999; Malumbres et al., 2004) . Although these two kinases share binding partners (D-type cyclins) and substrates, it appears from these mouse studies that Cdk4 and Cdk6 are more different than anticipated and might not completely compensate for each other. Inactivation of Cdk6 does not impair cell cycle progression, although the number of certain types of hematopoietic cells is reduced (Malumbres et al., 2004) . Lack of Cdk4 has a mild effect on cell cycle progression with a 4 h delay in S phase entry in mouse embryo fibroblasts (MEFs) from quiescence, and the cell number of several differentiated cell types (pancreatic b cells, anterior pituitary cells, Leydig cells) is decreased (Rane et al., 1999; Tsutsui et al., 1999) . The S phase delay observed in Cdk4 À/À MEFs is indirectly related to inhibition of Cdk2 activity. Indeed, Cdk4 À/À MEFs display decreased Cdk2 activity owing to the redistribution of p27, and combined inactivation of Cdk4-and p27-restored Cdk2 activity and S phase entry (Tsutsui et al., 1999) . Overall, none of the components of the cyclin D-associated complexes are required in early embryogenesis. In contrast, specific inhibition of cyclin D1 in cancer cell lines resulted in cell-cycle arrest (Zhou et al., 1995; Arber et al., 1997; Kornmann et al., 1998; Sauter et al., 1999; Lee et al., 2000) . Moreover, cyclin D1 or Cdk4-null mice are resistant to breast cancers triggered by the ErbB2 oncogene (Yu et al., 2001 Reddy et al., 2005; Landis et al., 2006) , skin tumor induced by 7,12-dimethylbenz[2]nthracene/12-O-tetradecanoylphorbol-13-acetate treatment (Robles et al., 1998; Rodriguez-Puebla et al., 2002) or c-myc overexpression (Miliani de Marval et al., 2004) . These results highlight a major difference between stem cell and cancer cell proliferation. Although Cdk4 activity is not detectable in stem cells (Savatier et al., 1994) , cancer cells often maintain The control of the cell cycle is essential to maintain a proper balance between proliferation and differentiation in most cells. Each cell type exhibits different proliferation characteristics and their response to the loss of Cdk activities varies. ES cells proliferate very rapidly and are independent of D-type cyclin activity. Moreover, they are not sensitive to the loss of other Cdks or cyclins (at least the ones that have been knockout), suggesting a high plasticity of the embryonic cell cycle. In contrast, differentiated cells have acquired a G1/S checkpoint, do not proliferate indefinitely and can enter quiescence (G0). The loss of Cdks or cyclins affects specifically certain types of differentiated cells. Cdk4/ cyclin D appears to be involved in a broad range of cell types. Combined inactivation of Cdk2 and Cdk4 affects cell proliferation during embryogenesis. Tumor cells are sometimes susceptible to Cdk inhibition, even if their proliferation features resemble the ones in stem cells (no G1/S checkpoint, no senescence, high telomerase activity, activation of proto-oncogenes, inactivation of tumor suppressor genes). Studying mouse models with inactivated Cdks or cyclins help us to better understand the specificity of the cell-cycle regulation in different cell types. high Cdk4 activity and are able to proliferate in the absence of mitogenic signals. Inhibition of cyclin D1 renders cancer cells dependent again on mitogenic signals.
So far, ablation of cyclins A2 and B1 are the only D/ E/A/B-type cyclin family members that result in early embryonic lethality, suggesting an essential role in cell proliferation or early development (Murphy et al., 1997; Brandeis et al., 1998) . However, cyclin B1-null embryos survive until mid-gestation (Brandeis et al., 1998) and cyclin A2-deficient embryos reach the blastocyst stage (Murphy et al., 1997) . This implies that at least early embryonic cycles can occur in the absence of cyclin B1 and A2. Cyclin A2 is apparently the most critical nonredundant cyclin in cultured somatic cells, as it is a ratelimiting component required for S-and M-phase progression (Furuno et al., 1999) . None the less, cyclin A2 activity was not detected in adult spleen or immortalized MEFs harvested from Cdk2-null mice (Berthet et al., 2003) , possibly uncovering another parallel pathway in cell cycle progression. The generation of conditional cyclin A2 knockout mice would help to further investigate these observations. Similarly, the cell-cycle community is waiting for the characterization of Cdk1 mouse models to uncover the mystery of a possible 'central' Cdk, comparable with Cdk1 that drives the yeast cell cycle by itself. The idea of a single essential Cdk in mammalian cells, like in yeast, started to make sense when it was demonstrated that Cdk2, the S phase regulating kinase, was not required for mitotic cell cycle (Berthet et al., 2003; Ortega et al., 2003) . Cdk2-null mice are viable and cell proliferation is barely affected with a 4 h delay observed in S phase entry in MEFs released from quiescence. We have shown using Cdk2
À/À mice that Cdk1 compensates for Cdk2, binds cyclin E and can promote the G1/S transition (Aleem et al., 2005) . Nevertheless, Cdk2 is essential for meiosis, indicating that Cdk1 cannot compensate for Cdk2 in germ cells (Berthet et al., 2003; Ortega et al., 2003) .
Silencing of Cdks in cell lines
In cancer cell lines, it appears that inhibition of Cdk1 or Cdk2, using siRNAs, has different effects depending on the cell lines tested. Cdk2 siRNA does not interfere with proliferation of several colon cancer cell lines or U2OS osteosarcoma cells (Tetsu and McCormick, 2003; Cai et al., 2006; Payton et al., 2006) . In contrast, Cdk2 siRNA delays G1 progression in NCI-H1299 non-small cell lung cancer cells (Cai et al., 2006) , induces G1 arrest in melanoma cells (Du et al., 2004) and results in accumulation of HT29 colon cancer cells in S and G2/M phases (Moffat et al., 2006) . Taken together with the fact that Cdk1 compensates for Cdk2 in mice (Aleem et al., 2005) , it is likely that in a wide variety of cell lines, Cdk1 can compensate for Cdk2. Nevertheless, there are some discrepancies, suggesting that compensatory mechanisms could be affected by genetic alterations in some cell lines and open the opportunity to use Cdk2-inhibitors in cancer therapy. Depletion of Cdk1 in NCI-H1299 or U2OS cells resulted in an accumulation in G2/M and a moderate slowing of G2/M progression after release from synchronization (Cai et al., 2006) . Moreover, U2OS cells have a greater propensity to undergo endoreplication, suggesting that these cells lack an efficient postmitotic checkpoint. Cdk1 silencing does not induce cytotoxicity in NCI-H1299 or U2OS cells and it might be compensated by Cdk2, as Cdk2/cyclin B complexes have been observed in Cdk1 knock down cells (Cai et al., 2006) .
Taken together, these results suggest that none of the cyclins or Cdks that have been mutated so far, affect early embryonic cell cycles and proliferation of stem cells does not seem to be dependent on a specific Cdk/ cyclin complex (the jury is still out for Cdk1). In contrast, proliferation of differentiated cells is affected specifically by the lack of at least one Cdk/cyclin complex. Cdk2 is important for germ cells, Cdk6/cyclin D complexes in hematopoietic cells, and Cdk4/cyclin D complexes appear to be important in a larger panel of cells. Inhibition of a single Cdk affects cancer cells moderately, but to a higher extent than it affects ES cells. Responses to Cdk inhibition varies in each cell line, which suggests that tumor cells exhibit specific sensitivities as has been seen in differentiated cells. In both cancer cells and differentiated cells, but not ES cells, Cdk4/cyclin D1 complexes seem to be required in a broad range of cell types.
Compound mouse mutants
Uncovering the compensatory mechanisms led to the development of complex mouse models to discriminate the functional overlap of cyclins or Cdks (reviewed by Pagano and Jackson (2004) ; Aleem and Kaldis (2006) ; Santamaria and Ortega (2006) ). Inactivation of D-type (D1, D2, D3) or E-type (E1, E2) cyclins has been reported, and surprisingly cell proliferation was not abolished (Geng et al., 2003; Parisi et al., 2003; Kozar et al., 2004) . The lack of cyclin E affects trophoblast endoreplication and cell cycle reentry of quiescent MEFs, but embryos reach birth when the placental defect is rescued (Geng et al., 2003) . Triple cyclin D knockout leads to late embryonic lethality owing to hematopoietic and cardiac defects, and in vitro cyclin D-deficient MEFs exhibit higher dependence on serum than wild-type cells (Kozar et al., 2004) . These phenotypes suggest that proliferation of ES cells is not dependent on cyclin D or cyclin E. This is not too surprising for the D-type cyclins, as Cdk4/cyclin D activity was not detected in ES cells and the unlimited abundance of growth factors during the early stages of embryonic development. The fact that E-type cyclins are also not essential for the entry into S phase corroborates that only cyclin A2 cannot be fully compensated in early embryogenesis. Double knockouts for Cdk2/Cdk4 and Cdk4/Cdk6 corroborate this view, as no early embryonic defects have been observed (Malumbres et al., 2004; . However (and maybe finally), a pronounced impairment of cell cycle progression has been observed in double knockouts of Cdk2 and Cdk4 . Combined loss of Cdk2 and Cdk4 leads to a progressive decrease of Rb phosphorylation after midgestation or in primary MEFs. Proliferation is reduced in vivo and the ability of cells to proliferate during embryogenesis is probably related to their dependence on the Rb/E2F pathway. Rb is always phosphorylated in stem cells (Savatier et al., 1994) and pocket protein functions are not required in stem cells (Dannenberg et al., 2000; Sage et al., 2000) . In double knockouts of Cdk2 and Cdk4, Rb is initially phosphorylated but a negative loop leads to concomitant decreases of Rb phosphorylation and transcription of E2F target genes . Among these genes, Cdk1 expression declines, which further decreases Rb phosphorylation. Several possibilities could explain this scenario, but overall it is associated with the number of divisions and/or the state of differentiation (Berthet and Kaldis, 2006) . In contrast, when Cdk6 is deleted in a Cdk2-null background, mice are viable and exhibit similar phenotypes that were observed in respective single knockouts (Malumbres et al., 2004) . Furthermore, combined inactivation of Cdk4 and Cdk6 affects hematopoietic differentiation, but not significantly cell proliferation (Malumbres et al., 2004) . These models emphasize the difference between Cdk4 and Cdk6 and demonstrate that Cdk2 and Cdk4 share a specific task in the control of Rb that can be compensated only in early embryogenesis. This indicates that mechanisms regulating the proliferation of stem cells and differentiated cells are different, especially in the G1/S transition. In differentiated cells, Cdk2 and Cdk4 contribute to coupling of the G1 phase to mitosis (Berthet and Kaldis, 2006) .
The Rb/E2F pathway is often inactivated in tumor cells, through hyper activation of G1 Cdk/cyclin complexes. In contrast to stem cells, combined inhibition of G1 Cdks could impact proliferation of tumor cells. To our knowledge, siRNAs or drugs that have been developed to target Cdk4/6 or Cdk1/2 specifically, have not yet been combined to inhibit both Cdk2 and Cdk4 in tumor models. On the other hand, combined depletion of Cdk1 and Cdk2 had a higher impact than single knockdown, inducing apoptosis in U2OS and a strong G2/M block in NCI-H1299 cells (Cai et al., 2006) . This confirms the mutual compensation between Cdk1 and Cdk2. Using Roscovitine, or even more specific Cdk1/2 inhibitors, also leads to cell-cycle arrest or apoptosis in several cell lines (Payton et al., 2006; Ribas et al., 2006; Wesierska-Gadek et al., 2006) . Surprisingly, Roscovitine can also protect thymocytes against apoptosis, and several groups suggest that Cdk2 might be required in these cells for programmed cell death (Gil-Gomez et al., 1998; Hakem et al., 1999) . Further investigations will be needed to determine the specific role of each Cdk depending on cell type; however, it is encouraging for tumor therapy to notice that combined inactivation of Cdks might impair tumor cell proliferation. Depending on tumor type, we might be able to modulate Cdk activity and initiate the most appropriate cell-cycle arrest and eventually trigger a cytotoxic effect exclusively to the tumor cells.
Control of senescence by Cdk/cyclin complexes
Normal cells undergo senescence in response to various stress signals, such as telomere shortening, oxidative stress, DNA damage or aberrant oncogene activation. Two major tumor-suppressor cascades, the p16
INK4a
-Rb and the ARF-p53-p21 pathways, are involved in senescence signaling, although differences exist between human and mouse cells (reviewed by Blasco (2005) ; Dimri (2005) ; Kiyokawa (2006) ). Mainly, mouse cells express telomerase and do not exhibit shortened telomeres. These pathways involve inhibition of Cdk4 by p16
INK4a or Cdk2 by p21, which suggests a central role for Cdks in senescence. Under regular culture conditions, MEFs express p16
INK4a and p19 ARF , which leads to Cdk inhibition and the hypo-phosphorylation of pocket proteins. The lack of the three pocket proteins or the acute inactivation of Rb is enough to bypass senescence (Dannenberg et al., 2000; Sage et al., 2000) . Similarly, p19 is essential and its absence leads to bypass of senescence and cells become immortal (Kamijo et al., 1997) . On the other hand, MEFs lacking p16 INK4a undergo senescence apparently normally, suggesting that p19 ARF -p53-p21 pathway might be more important in these cells (Sharpless et al., 2001) . Premature senescence has not been reported in MEFs deficient of Cdk4 or Cdk4/Cdk6, corroborating that p16
-Rb pathway is functional or not essential under these conditions. In contrast, Cdk2 À/À Cdk4 À/À MEFs enter senescence prematurely, which contributes to their lack of proliferation at passage 4 . The proliferation defect and premature senescence can be rescued by human papillomavirus-E7 infection, which inhibits all pocket proteins. A similar rescue of Cdk2
Cdk4
À/À MEFs is not observed in the absence of p27 (Cdk2
À/À MEFs), which enhances Cdk1 activity. These results suggest that inhibition of Cdk4 plays an important role in the regulation of senescence (see also Zou et al. (2002) ) and it highlights the cooperation of the signals through the p16-Cdk4-Rb and p19 ARF -p53-p21-Cdk2-Rb pathways. It is worth to note that p21 and p27 transcription is decreased in Cdk2 À/À Cdk4 À/À MEFs, similar to known E2F-target genes. It will be interesting to test if the inactivation of p19 ARF , p53 or p21 could modulate entry into senescence of Cdk2 À/À Cdk4 À/À MEFs. MEFs are convenient to study senescence, but other differentiated cell-types need to be investigated to better understand this signaling pathway and eventually target it in tumor cells. Similar to proliferation, behavior of tumor cells in terms of senescence might be different than ES cells. Both express telomerase and can divide unlimitedly. However, it has been shown by cell fusion experiments that senescence was dominant over immortality (Wadhwa et al., 1994; Bertram et al., 1999) and senescent cells can exist in premalignant tumors (Collado et al., 2005) . It has been suggested that ES cells are spontaneously immortal because telomerase, p53, Rb and IGF/Akt pathways are under strict regulation, whereas in tumor cells they are usually deregulated or lost (Miura et al., 2004) . We could envision that in some tumor cells (e.g., tumor associated with loss of p27), combined inhibition of Cdk2 and Cdk4 could lead to senescence, which could be used as a possible therapeutic approach.
Cdk/cyclin activity and apoptosis
Cdk activity has been suggested to contribute to apoptosis in different cell types. So far, this hypothesis has been proposed based on indirect evidence, and mouse knockouts of Cdks could provide new insights. The chemical inhibitor, Roscovitine, has been used in several models to investigate the potential role of Cdks. So far, it has been shown that Roscovitine can block apoptosis in thymocytes after radiation, dexamethasone, heat-shock or anti-CD3 treatment (Gil-Gomez et al., 1998; Hakem et al., 1999) . An apparent link between apoptosis and increase of Cdk2 activity has been observed, suggesting that Cdk2 is required for apoptosis associated with antigen-induced negative selection of thymocytes. Roscovitine blocks this apoptotic pathway independent of T-cell antigen-receptor rearrangements , suggesting a role independent of DNA repair, where Cdk2 could also be involved (Muller-Tidow et al., 2004) . Similarly, inhibition of Cdks attenuates apoptosis in terminally differentiated neurons (Monaco and Vallano, 2003; Appert-Collin et al., 2006) and prevents cisplatin-induced cytotoxicity in the kidney (Price et al., 2006) . In contrast, Roscovitine induces apoptosis in neutrophiles, which also are terminally differentiated cells (Rossi et al., 2006) . These non-proliferating cells apparently express Cdks, suggesting that these kinases may play a role unrelated to cell cycle. Their role as regulators of E2F/Rb pathway might correlate with the apoptotic function of E2F in such cells (reviewed by Stanelle and Putzer (2006) ). Cdks could potentially be involved in survival signals, but it is essential that we better understand this function to reconcile these contradictory results.
Several apoptosis-inducing agents enhance cyclin A-associated activity in HeLa cells and overexpression of Bcl2-suppressed apoptosis and reduced the amount of Cdk1 and Cdk2 in the nucleus (Meikrantz et al., 1994) . Moreover, combined silencing of Cdk1 and Cdk2 by siRNAs induces apoptosis in U2OS cell lines, but not in NCI-H1299 (Cai et al., 2006) . The limited cell death in NCI-H1299 cells was significantly increased by co-depletion of Cdk9, involved in transcriptional regulation. In fact, in U2OS cells, inhibition of Cdk1 and Cdk2 results in reduced expression of RNA polymerase II and its associated phosphorylated forms. These data suggest that combined effects on cell cycle progression and transcription occur in doubly depleted U2OS cells that could contribute to the apoptotic response (Cai et al., 2006) . The sensitivity of cell lines is probably related to their plasticity to adjust the inhibition of a specific Cdk. The cytotoxic effect on tumors might depend on the overlapping role of the Cdks to maintain survival signals.
Cdk/cyclin activity, checkpoints and tumor development Checkpoints are molecular events that manage the surveillance of cellular damage and eventually induce arrest of cell cycle progression. Each phase of the cell cycle and each type of damage is controlled by specific mechanisms, however, the end point remains the inhibition of Cdk/cyclin activity. This goal is achieved by stimulation of CKI expression, dephosphorylation of Cdks, cyclin degradation or cytoplasmic retention of Cdk/cyclin complexes (reviewed by Li and Zou (2005) ).
Mouse knockouts represent good models to study these molecular events in vivo and determine which Cdk activity is required or dispensable to maintain a normal checkpoint. Martin et al. (2005) have shown, for example, that Cdk2 was not required for p21-induced cell-cycle arrest after DNA damage. This suggests that compensatory mechanisms that contribute to maintain normal cell-cycle progression are also effective under stress conditions. However, lack of Cdks and cyclins could confer some resistance to tumors, indicating a difference between tumors and normal tissue. We mentioned that lack of cyclin D1 or Cdk4 confers resistance to breast or skin tumors (Robles et al., 1998; Yu et al., 2001 Yu et al., , 2006 Rodriguez-Puebla et al., 2002; Reddy et al., 2005; Landis et al., 2006) . Moreover, ablation of CKIs leads to multiple tumors, so it is possible to analyse the consequences of the lack of Cdk activity in the context of non-effective checkpoints (e.g., loss of CKIs, p53 or Rb). In this regard, Cdk2 À/À mice have been crossed with p27-null mice, which develop pituitary tumors (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . Surprisingly, similar tumors were observed in Cdk2
À/À mice and this lead to uncover that Cdk1 was an in vivo target of p27 and compensates for Cdk2 (Aleem et al., 2005) . On the other hand, inactivation of Cdk4 rescues tumor-free survival of p18
INK4cÀ/À mice (Pei et al., 2004) . These results highlight that CKIs, and generally tumorsuppressor genes, could have several targets in vivo and we must try to understand the crosstalk between the different pathways to be able to affect the proper target(s), if we want to re-establish cell-cycle arrest and eventually inhibit tumor growth.
Loss of proper G1/S control and loss of p53 are major events in tumor progression, directly affecting cell-cycle checkpoints. With the development of more complex mouse models, it would be interesting to test whether inhibition of multiple Cdks will affect tumor growth. This question should be addressed in the context of p53 or Rb deficiency. The crosstalk between the Rb/E2F and p53 pathways is sometimes difficult to address, and we wonder what are the consequences of p53 mutation in combination with the loss of one or more Cdks.
Conclusions
Inhibition of Cdk activity has been a target for many years aiming to decrease proliferation in tumor cells. We are hoping that the development of mouse models lacking Cdks would help us to determine which cell types are dependent critically on a specific Cdk. It seems that redundancy is more abundant than initially suspected. However, it remains true that some differentiated cells are dependent on a defined Cdk/cyclin complex. In contrast, ES cells seem to be able to fully compensate for the lack of multiple Cdks. These mouse models highlight the fact that cell cycle regulation is very different in ES cells compared with differentiated cells. When proliferation in tumor cells is investigated, it appears that they behave like stem cells. However, when analysing data that was accumulated from tumor cell lines, it appears that proliferation can be affected by the inhibition of Cdk activity and tumor cells behave more like specific differentiated cell types. It has been even suggested that, in some case, tumor cells are derived from adult stem cells. This possibility could explain this discrepancy, as adult stem cells exit the 'embryonic' cell cycle and enter quiescence (Figure 2) . Such tumor cells can acquire characteristics of the cell cycle of differentiated cells, which renders them dependent on Cdks (see Figure 1) . Our challenge now is to identify which loss of Cdk activity can lead to growth arrest, senescence or apoptosis, in the context of specific human tumors. Using mouse models lacking Cdks or cyclins, an in vivo tumor models will help to further investigate the potential of Cdk inhibition in cancer therapy. It is likely that each tumor type will have its own specificity, similar to what we observed in our mouse models and in differentiated cell types.
